机构:[1]Department of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[2]Department of Hepato-Biliary-Pancreatic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省肿瘤医院
Background: The value of anatomic resection (AR) in intrahepatic cholangiocarcinoma (ICC) remains controversial. This study compares the perioperative safety and long-term outcomes of AR versus nonanatomic resection (NAR) in ICC patients. Methods: A systematic search was conducted in PubMed, Medline, Embase, Cochrane Library, China National Knowledge Infrastructure(CNKI), and Wanfang database for prospective or retrospective studies comparing the efficacy of AR and NAR in, ICC published to 1 June 2024. Meta-analyses were performed on surgical factors, perioperative outcomes, and long-term prognosis for both the entire cohort and the propensity score-matched (PSM) cohort. The primary outcome measures were overall survival (OS) and disease-free survival (DFS). Results: Seven studies, including 1801 ICC patients, were analyzed. In both the entire and the PSM cohort, the AR group demonstrated superior OS (HR=0.71, 95% CI=0.57-0.88, P=0.002 and HR=0.70, 95% CI=0.59-0.83, P<0.0001, respectively) and DFS (HR=0.75, 95% CI=0.62-0.91, P=0.004 and HR=0.68, 95% CI=0.58-0.79, P<0.00001, respectively) compared to the NAR group. AR significantly improves 1-year, 3-year, 5-year DFS, and 5-year OS(all P<0.05). In the PSM cohort, AR and NAR groups showed comparable blood loss, operative times, overall complications, and major complications (all P>0.05). Subgroup analysis revealed that among patients with tumor >5 cm, AR achieved better OS and DFS, whereas patients with tumors <= 5 cm did not experience survival benefits from AR. Conclusion: This study suggests that AR, compared to NAR, can improve OS and DFS without increasing perioperative risks, particularly in ICC patients with tumors larger than 5 cm.
基金:
National multi-disciplinary collaborative diagnosis and treatment capacity building project for major diseases [TJZ202104]; Natural Science Foundation of China [82173248, 82272685, 82002967, 82202260]; Postdoctoral Science the fellowship of China National Postdoctoral Program for Innative Talents [BX20200225]; China Postdoctoral Science Foundation [2022TQ0221]; Science and Technology Major Program of Sichuan Province [2022ZDZX0019]; Sichuan Science and Technology Program [2023YFS0128, 2023NSFSC1874, 2021YJ0420]; The 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYJC18008, ZYGD22006]; Sichuan University postdoctoral interdisciplinary Innovation Fund [10822041A2103]
第一作者机构:[1]Department of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Jiang Chuang,Hou Gui-Min,Zhang Zhi-Hong,et al.Anatomic versus nonanatomic resection for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J].INTERNATIONAL JOURNAL OF SURGERY.2025,111(1):1440-1453.doi:10.1097/JS9.0000000000002134.
APA:
Jiang, Chuang,Hou, Gui-Min,Zhang, Zhi-Hong,Qiang, Ze-Yuan,Wang, Hai-Chuan...&Zeng, Yong.(2025).Anatomic versus nonanatomic resection for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.INTERNATIONAL JOURNAL OF SURGERY,111,(1)
MLA:
Jiang, Chuang,et al."Anatomic versus nonanatomic resection for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis".INTERNATIONAL JOURNAL OF SURGERY 111..1(2025):1440-1453